Novel therapeutic agents for B-cell lymphoma: developing rational combinations.
Several novel targeted therapies have recently emerged as active in the treatment of non-Hodgkin lymphoma, including small molecules that inhibit critical signaling pathways, promote apoptotic mechanisms, or modulate the tumor microenvironment. Other new agents target novel cell surface receptors or promote DNA damage. Although most of these drugs have single-agent activity, none have sufficient activity to be used alone. This article reviews the utility and potential role of these new agents in the treatment of non-Hodgkin lymphoma with a specific focus on data that highlight how these agents may be incorporated into current standard treatment approaches.
Division of Hematology and Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA. reeder.craig@mayo.edu
Craig B
CB
Reeder
Stephen M
SM
Ansell
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000378:metabolism / Q000628:therapy*
D000970:Antineoplastic Agents